Clinical Trial Update: TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Transarterial Chemoembolization (TACE) plus sorafenib versus TACE alone in recurrent intermediate hepatocellular carcinoma has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Hepatocellular Carcinoma, Sorafenib | Phase 3 | Status: COMPLETED